Immunic Announces Grant of Key European PatentProtecting Relevant Dosing Regimens for Vidofludimus Calcium  – Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 – – Broad Protection Extends to All Forms of Vidofludimus, Including Its Salts, Solvates and Free Aci [ … ]

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update – Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 –  – Raised Proceeds of $200 Million in a Private Placement, with Potential for up to an Additional $200 Million –  – Net Proceeds Expecte [ … ]